Addressing Health Technology Policy Issues: The Canadian Way

Introduction to the Policy Forum

Joan Berezanski
Chair, Policy Forum

April 16, 2012
The Health Technology Strategy Policy Forum

• Created in response to *Health Technology Strategy 1.0 (HTS 1.0)* and the subsequent *Implementation Strategy*, approved by the Conference of Deputy Ministers.

• One of the primary goals is to prevent a “whipsawing” effect across jurisdictions.
Mandate

• To provide federal, provincial, and territorial jurisdictions with opportunities to share information and collaborate on health technology policy development.

• To provide strategic policy advice on health technologies to CADTH.
Membership

- One voting member from each of the federal, provincial, and territorial jurisdictions
- One representative from Health Canada, Industry Canada, and from Interprovincial and Territorial Medical Directors group
- Members typically have decision-making responsibilities in their jurisdictions.
Policy Forum Relationships

- Reports to the CADTH Board of Directors as delegated by the Conference of Deputy Ministers

- Receives secretariat support from CADTH

- Provides strategic policy advice to CADTH

- Collaborate with the Health Technology Analysis Exchange (Exchange)

- Collaborate with the Health Technology Expert Review Panel (HTERP)
Examples of Activities

• Policy Information and Option Documents
  - Examples: Use of PET in Oncology in Canada; Renal Replacement Therapy in Critical Care

• Discussion Papers
  - Examples: Managing Technology Diffusion; Reassessment of Health Technologies: Obsolescence and Waste

• Commissioning specific Health Technology Inquiry Service (HTIS) Reports from CADTH
  - Examples: Sleep Apnea; Intraocular Lenses

• Wider Table Event
Strategic Priorities 2011–2014

- Appropriateness of diagnostic imaging
- Predictive genetic testing
- Common technology review
Future Direction

• Becoming more established and ironing out processes.
• Increased dialogue with CDM, industry, professional associations, public, lobby groups, etc.
• More interaction with international community.
• More proactive approach.
• Established common health technology review.
• Demonstrated impact on cost curve.